The Centers for Medicare and Medicaid Services released a final rule this week ending federal Medicaid and Children's Health Insurance Program funding for what the agency calls "sex-rejecting procedures" in minors. It is scheduled to take effect on October 13, 2026.
What the rule does is narrower than much of the coverage of it suggests, and the distinction determines who is actually affected.
The rule withdraws federal matching funds. It does not prohibit states from covering the same services using state dollars alone, nor does it directly regulate what physicians or hospitals may do.
What the Rule Withdraws, and from Whom
Under the final rule, states can no longer draw federal matching funds for the specified interventions provided to Medicaid beneficiaries younger than 18, or to CHIP enrollees younger than 19 in certain states.
CMS defines the covered interventions to include puberty-blocking medications, cross-sex hormone therapy, and surgical procedures intended to align a minor's body with a gender identity discordant from sex.
Medicaid is jointly financed. The federal government pays a share of each state's costs, and this rule targets that share. The American Hospital Association noted in its summary that the final rule does not prevent states from providing coverage with state-only funds.
Whether states do so is a budget question rather than a legal one, and it will vary. CMS said in December 2025 that 27 states did not already provide Medicaid coverage for these services for children, and analyses of the final rule indicate that it directly affects roughly 17 state Medicaid programs that currently cover one or more of these services. In those states, the practical effect depends on whether legislatures replace the federal share.
The Six-Month Tapering Provision
The rule includes a transition period that has drawn clinicians' attention.
Federal Medicaid and CHIP funding remains available for up to six months from the effective date for children currently receiving hormone therapy, which CMS describes as a tapering-off period.
That is a limited window. It applies to existing hormone therapy rather than to new starts, and it addresses a clinical reality that abrupt discontinuation of hormone therapy is not a neutral event physiologically.
CMS also states that the rule does not affect coverage of mental health services. Medicaid's Early and Periodic Screening, Diagnostic, and Treatment provisions continue to require comprehensive mental health coverage for eligible children, and CHIP continues to require coverage of necessary mental health services under federal law. In the proposed rule, the agency stated that it permits coverage of other services, such as psychotherapy, which it said do not carry the same concerns as the pharmaceutical and surgical interventions the rule defines.
What CMS Says, and What Critics Say
CMS grounded the rule in an evidence review. The agency said its decision followed a review of national and international research by the Department of Health and Human Services, which identified significant evidence gaps, documented safety concerns, and concluded that the evidence supporting these interventions for children was insufficient to justify federal taxpayer funding.
HHS Secretary Robert F. Kennedy Jr. said the department is ending federal taxpayer funding for the procedures, which can cause irreversible harm. CMS Administrator Mehmet Oz said in the agency's announcement that the rule is "protecting children from potentially irreversible harm so they can truly flourish."
CMS cited the United Kingdom's Cass Review, along with restrictions adopted in other countries and states and shifts in the positions of some medical organizations, as evidence that clinical consensus is moving.
Opponents dispute both the evidence reading and the mechanism. Major US medical organizations, including the American Medical Association and the American Academy of Pediatrics, have supported this care and insurance coverage for it. In comments filed on a companion proposal, legal and social science scholars at the UCLA Williams Institute argued the evidence CMS relied on was flawed and that the agency had not met the standard for reasoned decision-making. The California Health and Human Services Agency urged CMS in a joint comment letter to withdraw the proposal, arguing it would eliminate access to care the agency considers evidence-based.
Readers should also note that surgery in this age group is uncommon. CMS's own analysis of claims data found that the large majority of relevant pediatric spending went to hormone therapy rather than surgery.
The Money, and the Rule That Has Not Been Finalized
CMS estimated the fiscal effect using 2023 claims data, which showed roughly $31 million in combined federal and state Medicaid and CHIP spending on the relevant services for beneficiaries 17 and younger that year. States that had not already restricted these services accounted for about three-quarters of that spending.
Projections for the coming decade vary depending on which spending streams are counted and whether figures are expressed in real 2027 dollars. Published summaries of the rule's regulatory impact analysis cite federal reductions ranging from $138 million to about $175 million for fiscal years 2027 through 2036, with state Medicaid spending falling by an additional $97 million, for a combined reduction of roughly $235 million.
Against total Medicaid spending, those are small figures, which is part of why both supporters and opponents have framed the rule primarily in terms of policy signal rather than budget.
One thing is not settled. This final rule is one of two proposals CMS issued in December 2025. The second, a proposed Condition of Participation that would bar Medicare- and Medicaid-participating hospitals from providing this care to minors at all, drew comments through February 17, 2026, and has not yet been finalized. That rule, not this one, would carry the broader effect on hospitals, because nearly all US hospitals participate in Medicare and Medicaid.
Families currently receiving care through Medicaid or CHIP should contact their state Medicaid agency and their treating clinician about what changes after the effective date, since the answer depends on the state. The full text is available through the HHS release, which links to the Federal Register version.
Key Questions Answered
What exactly does the rule do? It bars states from drawing federal Medicaid matching funds for puberty-blocking medications, cross-sex hormone therapy, and related surgical procedures provided to Medicaid beneficiaries under 18, and bars federal CHIP funding for enrollees under 19 in certain states. It takes effect on October 13, 2026.
Does it ban this care? No. The rule withdraws federal financial participation. It does not prohibit states from covering the same services with state-only funds, nor does it directly regulate what physicians or hospitals may do.
How many states are actually affected? CMS said 27 states already did not provide Medicaid coverage of these services for children. Published analyses indicate the rule directly affects roughly 17 state Medicaid programs that currently cover one or more of them.
What happens to children already receiving hormone therapy? Federal Medicaid and CHIP funding remains available for a tapering-off period of up to six months from the effective date for children currently on hormone therapy. The provision applies to existing treatment, not new starts.
Does the rule affect mental health coverage? CMS states that it does not. Medicaid's Early and Periodic Screening, Diagnostic, and Treatment provisions continue to require comprehensive mental health coverage for eligible children, and CHIP requirements are unchanged.
How much money is involved? CMS identified roughly $31 million in combined federal and state Medicaid and CHIP spending on these services in 2023. Decade-long projections cited in published summaries range from $138 million to about $175 million in federal reductions, with roughly $235 million in combined federal and state reductions.
Is there another rule still pending? Yes. A separate proposed Condition of Participation that would bar Medicare- and Medicaid-participating hospitals from providing this care to minors drew comments through February 17, 2026, and has not yet been finalized. Because nearly all US hospitals participate in those programs, that rule would have a broader effect.
